| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $6.7M | — | -12.3% |
| SG&A Expense | $3.8M | — | -1.0% |
| Operating Income | -$10.6M | — | +8.5% |
| Net Income | -$10.0M | — | +5.8% |
| EPS (Basic) | -$0.29 | — | +17.1% |
| EPS (Diluted) | -$0.29 | — | +17.1% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $53.5M | +168.2% | +167.6% |
| Current Assets | $87.5M | +46.0% | +25.8% |
| Total Assets | $87.5M | +41.2% | +7.6% |
| Current Liabilities | $5.6M | -36.2% | — |
| Total Liabilities | $5.7M | -35.5% | -28.5% |
| Stockholders' Equity | $81.8M | +54.1% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$12.1M | — | -13.6% |
| Investing Cash Flow | $8.3M | — | -9.8% |
| Financing Cash Flow | $37.3M | — | — |
| +11.5% |